Rtw Investments, LP Immunovant, Inc. Transaction History

Rtw Investments, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 13, 2021	SELL	$9.4 - $16.85 $59.8 Million - $107 Million	-6,356,743 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$13.08 - $49.6 $16.2 Million - $61.3 Million	-1,235,510 Reduced 16.27%	6,356,743 $102 Million
Q4 2020 Feb 16, 2021	BUY	$36.36 - $52.71 $2.98 Million - $4.31 Million	81,841 Added 1.09%	7,592,253 $351 Million
Q3 2020 Nov 16, 2020	BUY	$22.61 - $38.9 $40.5 Million - $69.8 Million	1,793,230 Added 31.37%	7,510,412 $264 Million
Q2 2020 Aug 14, 2020	BUY	$13.87 - $28.44 $17.9 Million - $36.7 Million	1,291,076 Added 29.17%	5,717,182 $139 Million
Q4 2019 Feb 14, 2020	BUY	$10.02 - $16.4 $44.3 Million - $72.6 Million	4,426,106 New	4,426,106 $66 Million

211

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Rtw Investments, LP, based on Form 13F filings with the SEC.

Stay updated on Rtw Investments, LP with notifications on news.